Another paper on positive results of #Chloroquine-Azithromycin intervention in #Covid_19 patients. Impressive results and reduction in viral load and early discharge! mediterranee-infection.com/pre-prints-ihu/ 
Three in vitro studies have demonstrated that chloroquine phosphate inhibits SARS-CoV-2 (8;9) and two have demonstrated that hydroxychloroquine sulfate inhibits SARS-CoV-2 (8-10).
In addition, chloroquine has demonstrated its efficacy in Chinese COVID-19 patients in clinical trials by reducing fever, improving CT imaging, and delaying disease progression
In a preliminary clinical trial on a small cohort of COVID-19 patients, we demonstrated that those treated with hydroxychloroquine (600 mg per day, N=20 patients) had a significant reduction in viral carriage at D6-post inclusion, with 70% of patients testing negative
In addition, of the twenty patients who were treated with hydroxychloroquine, six received azithromycin for five days (for the purposes of preventing bacterial super-infection) and all (100%) were virologically cured at D6
The time between the onset of symptoms and hospitalisation was on average five days, with the longest time being 17 days. 53.8% of patients presented with LRTI symptoms and 41.2% with URTI symptoms.
it is necessary to avoid a negative evolution of pneumonia, which usually occurs around the tenth day and may result in acute respiratory distress syndrome, the prognosis of which, in particular in the elderly, is always poor, whatever the cause.
The primary therapeutic objective is therefore to treat people who have moderate or severe infections at an early enough stage to avoid progression to a serious and irreversible condition.
By administering hydroxychloroquine combined with azithromycin, we were able to observe an improvement in all cases, except in one patient who arrived with an advanced form, who was over the age of 86, and in whom the evolution was irreversible.
For all other patients in this cohort of 80 people, the combination of hydroxychloroquine and azithromycin resulted in a clinical improvement that appeared
significant when compared to the natural evolution in patients
significant when compared to the natural evolution in patients
The favourable evolution of our patients under hydroxychloroquine and azithromycin was associated with a relatively rapid decrease in viral RNA load as assessed by PCR, which was even more rapid when assessed by culture.
These data are important to compare with that of the literature which shows that the viral RNA load can remain high for about three weeks in most patients in the absence of specific treatment
Chloroquine and hydroxychloroquine are extremely well-known drugs which have already been prescribed to billions of people.
In conclusion, we confirm the efficacy of hydroxychloroquine associated with azithromycin in the treatment of COVID-19 and its potential effectiveness in the early impairment of contagiousness.
